These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 30963603)

  • 1. A Frizzled-Like Cysteine-Rich Domain in Glypican-3 Mediates Wnt Binding and Regulates Hepatocellular Carcinoma Tumor Growth in Mice.
    Li N; Wei L; Liu X; Bai H; Ye Y; Li D; Li N; Baxa U; Wang Q; Lv L; Chen Y; Feng M; Lee B; Gao W; Ho M
    Hepatology; 2019 Oct; 70(4):1231-1245. PubMed ID: 30963603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inactivation of Wnt signaling by a human antibody that recognizes the heparan sulfate chains of glypican-3 for liver cancer therapy.
    Gao W; Kim H; Feng M; Phung Y; Xavier CP; Rubin JS; Ho M
    Hepatology; 2014 Aug; 60(2):576-87. PubMed ID: 24492943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The oncogenic effect of sulfatase 2 in human hepatocellular carcinoma is mediated in part by glypican 3-dependent Wnt activation.
    Lai JP; Oseini AM; Moser CD; Yu C; Elsawa SF; Hu C; Nakamura I; Han T; Aderca I; Isomoto H; Garrity-Park MM; Shire AM; Li J; Sanderson SO; Adjei AA; Fernandez-Zapico ME; Roberts LR
    Hepatology; 2010 Nov; 52(5):1680-9. PubMed ID: 20725905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human Monoclonal Antibody Targeting the Heparan Sulfate Chains of Glypican-3 Inhibits HGF-Mediated Migration and Motility of Hepatocellular Carcinoma Cells.
    Gao W; Kim H; Ho M
    PLoS One; 2015; 10(9):e0137664. PubMed ID: 26332121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glypican-3 binds to Frizzled and plays a direct role in the stimulation of canonical Wnt signaling.
    Capurro M; Martin T; Shi W; Filmus J
    J Cell Sci; 2014 Apr; 127(Pt 7):1565-75. PubMed ID: 24496449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Both glypican-3/Wnt/β-catenin signaling pathway and autophagy contributed to the inhibitory effect of curcumin on hepatocellular carcinoma.
    Hu P; Ke C; Guo X; Ren P; Tong Y; Luo S; He Y; Wei Z; Cheng B; Li R; Luo J; Meng Z
    Dig Liver Dis; 2019 Jan; 51(1):120-126. PubMed ID: 30001951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soluble glypican 3 inhibits the growth of hepatocellular carcinoma in vitro and in vivo.
    Zittermann SI; Capurro MI; Shi W; Filmus J
    Int J Cancer; 2010 Mar; 126(6):1291-301. PubMed ID: 19816934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling.
    Capurro MI; Xiang YY; Lobe C; Filmus J
    Cancer Res; 2005 Jul; 65(14):6245-54. PubMed ID: 16024626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long noncoding RNA glypican 3 (GPC3) antisense transcript 1 promotes hepatocellular carcinoma progression via epigenetically activating GPC3.
    Zhu XT; Yuan JH; Zhu TT; Li YY; Cheng XY
    FEBS J; 2016 Oct; 283(20):3739-3754. PubMed ID: 27573079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glypican-3: a marker and a therapeutic target in hepatocellular carcinoma.
    Filmus J; Capurro M
    FEBS J; 2013 May; 280(10):2471-6. PubMed ID: 23305321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistent Polyfunctional Chimeric Antigen Receptor T Cells That Target Glypican 3 Eliminate Orthotopic Hepatocellular Carcinomas in Mice.
    Li D; Li N; Zhang YF; Fu H; Feng M; Schneider D; Su L; Wu X; Zhou J; Mackay S; Kramer J; Duan Z; Yang H; Kolluri A; Hummer AM; Torres MB; Zhu H; Hall MD; Luo X; Chen J; Wang Q; Abate-Daga D; Dropulic B; Hewitt SM; Orentas RJ; Greten TF; Ho M
    Gastroenterology; 2020 Jun; 158(8):2250-2265.e20. PubMed ID: 32060001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New tumor suppressor microRNAs target glypican-3 in human liver cancer.
    Cartier F; Indersie E; Lesjean S; Charpentier J; Hooks KB; Ghousein A; Desplat A; Dugot-Senant N; Trézéguet V; Sagliocco F; Hagedorn M; Grosset CF
    Oncotarget; 2017 Jun; 8(25):41211-41226. PubMed ID: 28476031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapamycin inhibits lung squamous cell carcinoma growth by downregulating glypican-3/Wnt/β-catenin signaling and autophagy.
    Bi Y; Jiang Y; Li X; Hou G; Li K
    J Cancer Res Clin Oncol; 2021 Feb; 147(2):499-505. PubMed ID: 33225417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of antiglypican-3 therapy as a promising target for amelioration of hepatic tissue damage in hepatocellular carcinoma.
    Zaghloul RA; El-Shishtawy MM; El Galil KH; Ebrahim MA; Metwaly AA; Al-Gayyar MM
    Eur J Pharmacol; 2015 Jan; 746():353-62. PubMed ID: 25449037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of glypican-3 expression via RNA interference influences the growth and invasive ability of the MHCC97-H human hepatocellular carcinoma cell line.
    Ruan J; Liu F; Chen X; Zhao P; Su N; Xie G; Chen J; Zheng D; Luo R
    Int J Mol Med; 2011 Oct; 28(4):497-503. PubMed ID: 21617840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncogenic activation of glypican-3 by c-Myc in human hepatocellular carcinoma.
    Li L; Jin R; Zhang X; Lv F; Liu L; Liu D; Liu K; Li N; Chen D
    Hepatology; 2012 Oct; 56(4):1380-90. PubMed ID: 22706665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glypican-3-mediated oncogenesis involves the Insulin-like growth factor-signaling pathway.
    Cheng W; Tseng CJ; Lin TT; Cheng I; Pan HW; Hsu HC; Lee YM
    Carcinogenesis; 2008 Jul; 29(7):1319-26. PubMed ID: 18413366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma.
    Lai JP; Sandhu DS; Yu C; Han T; Moser CD; Jackson KK; Guerrero RB; Aderca I; Isomoto H; Garrity-Park MM; Zou H; Shire AM; Nagorney DM; Sanderson SO; Adjei AA; Lee JS; Thorgeirsson SS; Roberts LR
    Hepatology; 2008 Apr; 47(4):1211-22. PubMed ID: 18318435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Shed antigen-induced blocking effect on CAR-T cells targeting Glypican-3 in Hepatocellular Carcinoma.
    Sun L; Gao F; Gao Z; Ao L; Li N; Ma S; Jia M; Li N; Lu P; Sun B; Ho M; Jia S; Ding T; Gao W
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33833049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA-133b inhibits hepatocellular carcinoma cell progression by targeting Sirt1.
    Tian Z; Jiang H; Liu Y; Huang Y; Xiong X; Wu H; Dai X
    Exp Cell Res; 2016 May; 343(2):135-147. PubMed ID: 27090017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.